COVID-VIT
Проводит Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
Страница компанииThe Efficacy of Vitamin D Supplementation in Patients With Severe and Extremely Severe COVID-19
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT05092698/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–100 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 110 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (01.2022) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 1 · невключение: 4
Критерии включения
- all patients with COVID-19 admitted to the ICU with vitamin D deficiency \[25-hydroxyvitamin D (25(OH)D) ≤ 30 ng/ml\]
Критерии невключения
- less than 24 hours in ICU by any reason
- chronic decompensated disease with extrapulmonary organ dysfunction (tumour progression, liver cirrhosis, congestive heart failure) with a life expectancy of less than 48 hours
- atonic coma
- allergic reaction on cholecalciferol or herbal oil
Источник: ClinicalTrials.gov, NCT05092698 · запись обновлена в реестре 7 марта 2022.
Дизайн и результаты
Что измеряют — первичные конечные точки (10), вторичных — 6
- Сomplete blood count — Change from baseline on day 5 during ICU treatment
- Сomplete blood count dynamics 1 — Change from baseline on day 10 during ICU treatment
- Сomplete blood count dynamics 2 — Change from baseline on day 15 during ICU treatment
- Сomplete blood count dynamics 3 — Change from baseline on day 21 during ICU treatment
- C-reactive protein — Change from baseline on day 5 during ICU treatment
- C-reactive protein 1 — Change from baseline on day 10 during ICU treatment
- C-reactive protein 2 — Change from baseline on day 15 during ICU treatment
- C-reactive protein 3 — Change from baseline on day 21 during ICU treatment
- Von Willebrand factor antigen — Change from baseline on day 7 during ICU treatment
- Thrombotic complications — 60 days
Цель исследования
Despite the successful treatment of patients with moderate coronavirus disease 2019 (COVID-19), outcomes for patients with severe disease remain unsatisfactory. In this category of patients, the course of the disease is complicated by the development of acute respiratory distress syndrome (ARDS) and the need for mechanical ventilation in the intensive care unit (ICU). Mortality in this category of patients reaches 85%. The lack of effective treatment for COVID-19 has prompted scientists to look for new strategies to reduce the incidence and severity of COVID-19, disease progression, and mortality.
Disease severity and mortality rates due to COVID-19 infection are greater in the elderly and chronically ill patients, populations at high risk for vitamin D deficiency. Vitamin D plays an important role in immune function and inflammation.
A number of experimental studies have shown that stimulation of vitamin D receptors can improve the course of ARDS due to inhibition of the hyperimmune inflammatory response, regulation of the renin-angiotensin system, modulation of neutrophil activity, maintenance of the integrity of the pulmonary epithelial barrier and stimulation of epithelial repair, as well as by reducing hypercoagulation.
Several studies on ICU patients have reported that low vitamin D (25(OH)D) concentrations are associated with a higher risk of negative outcomes such as death, organ failure, prolonged mechanical ventilation, a higher rate of ventilation-associated pneumonia, and sepsis.
While the available evidence to-date, from largely poor-quality observational studies, may be viewed as showing a trend for an association between low serum 25(OH)D levels and COVID-19 related health outcomes, this relationship was not found to be statistically significant. Calcifediol supplementation may have a protective effect on COVID-19 related ICU admissions.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT05092698 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.